GSK plc
Researches, develops and manufactures vaccines, specialty medicines and general medicines for disease prevention and treatment globally, with particular focus on oncology, respiratory conditions and immunology.
As of Aug 28, 2026
Summary
GSK plc is a London-listed pharmaceutical and consumer health company with a market value of £74.2 billion. The stock trades at a bearish technical bias despite posting a gain of 28.1% over the past year, though it has fallen 4.5% in the last month at a current price of 1,854p.
Price history
As of Aug 28, 2026
Performance
+0.00%
-3.39%
-4.45%
+1.82%
+1.62%
+28.09%
As of Aug 28, 2026
Technical indicators
- 41.4
- -1.96Bearish
- 50: 1930.57 · 200: 1947.41Bearish
- 1,850p / 1,937p
Technical Bias
Bearish lean
GSK plc trades at 1,854p, just above its support level of 1,850p. The technical indicators collectively suggest a bearish bias: MACD sits negative at −1.96, and the price is trading below both its 50-day moving average (1,930.57p) and 200-day average (1,947.41p), whilst RSI at 41.4 remains neutral. This is a derived technical read, not a recommendation.
A transparent read of the indicators below — not a prediction or recommendation.
As of Aug 28, 2026
Fundamentals
- £74.2B
- 15.71
- 1.18p
- 14.52%
- +5.3%
- £5.96B
- 0.3
- 1,440p – 2,281p
- 3.67%
- Aug 13, 2026
- Oct 28, 2026 (57 days)
As of Aug 31, 2026
Upcoming catalysts
- Earnings report
As of Aug 31, 2026
Latest news
As of Aug 31, 2026
MonkeyTrade's Take on GSK plc
Short-term outlook
The short-term setup leans bearish for GSK: price sits below both its 50-day (1,930.57p) and 200-day (1,947.41p) averages, MACD confirms the downward pull, and shares are down 4.5% over the past month. A break of 1,850p support would reinforce the bearish trend, while reclaiming 1,937p resistance is needed to challenge it. No earnings catalyst is imminent, with the next report not due until October 2026.
Medium-term outlook
GSK's fundamentals look solid enough for the medium term: revenue growing at 5.3%, a healthy 14.5% margin, a 3.7% dividend yield, and a modest 15.71 P/E that doesn't demand much optimism to justify. Yet the technical lean is bearish, suggesting the market isn't yet rewarding that steady growth. A sustained turn higher in the shares, confirming buyers are stepping back in, would be the signal needed to shift this cautious read.
Key risks
- Heavy investment in new ventures like the Cambridge research hub and the Relation Therapeutics partnership carries execution risk, with returns likely years away.
- GSK's growth increasingly leans on HIV franchises such as ViiV's Cabenuva, so any competitive or clinical setback in that portfolio could weigh on results.
- The shares sit well below their 52-week high of 2,281p, current at 1,854p, suggesting sentiment or fundamentals have cooled from earlier peaks.
- A low beta of 0.3 points to relatively muted share-price sensitivity to broader market moves, which can also mean less upside participation if healthcare sentiment improves.
About GSK plc
GSK plc is a UK-based pharmaceutical group listed on the London Stock Exchange, operating in the healthcare sector within drug manufacturing. With a market capitalisation of £74.2B, it sits among the larger players in the global pharma industry, developing and supplying medicines and vaccines across a broad range of therapeutic areas. Its scale and sector positioning make it one of the names investors often look to when tracking the healthcare space.
GSK's key figures point to a business valued at a price-to-earnings ratio of 15.71, reflecting how the market currently prices its earnings relative to its share price. The dividend yield of +3.7% shows the proportion of income returned to shareholders relative to the share price, a figure often of interest to those researching income-generating stocks within the healthcare sector.
How to trade GSK plc
Shares like this are usually traded as CFDs. Compare regulated brokers that offer share CFDs — weigh spreads, fees and platforms before you open an account.
AI-assisted research for informational purposes only — not investment advice. Figures are sourced from third-party market data and may be delayed. Do your own research before trading. Your capital is at risk. How we build these pages.